Trial Profile
Comparative usability of certolizumab pegol auto-injection device with other anti-tumor necrosis factor devices (adalimumab, etanercept and golimumab) in patients with moderate to severe rheumatoid arthritis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 30 Aug 2016
Price :
$35
*
At a glance
- Drugs Certolizumab pegol (Primary) ; Adalimumab; Etanercept; Golimumab
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- 30 Aug 2016 New trial record